1036926-69-8

Basic information

• Product Name: methyl 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoate
• Synonyms: methyl 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoate
• CAS NO: 1036926-69-8
• Molecular Weight: 481.351
• Mol File: 1036926-69-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: methyl 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoate(1036926-69-8)
• EPA Substance Registry System: methyl 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoate(1036926-69-8)

Safety Data

• Hazardous Substances Data: 1036926-69-8(Hazardous Substances Data)

Upstream product

• 1036926-67-6 4-bromo-2-(3,4-dichloro-phenyl)-butyric acid methyl ester 
• 1036926-61-0 6-fluorospiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one hydrochloride 
• 1036926-74-5 2-(3,4-dichloro-phenyl)-4-oxo-butyric acid methyl ester 
• 92926-32-4 6-fluorospiro[3,1-benzoxazine-4,4'-piperidin]-2(1h)-one 

Downstream Products

• 1036926-71-2 2-(3,4-dichlorophenyl)-4-(6-fluoro-2-oxo-1,2-dihydro-1'H-spiro[3,1-benzoxazine-4,4'-piperidin]-1'-yl)butanoic acid hydrochloride 

Relevant articles and documents

SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS

The present invention relates to a compound of formula (I) wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, lower hydroxyalkyl or -(CHR5)x-A; R5 is hydrogen, lower alkyl or lower hydroxyalkyl, or is heteroaryl optionally substituted by lower alkyl; A is cycloalkyl, aryl, heterocyclyl or heteroaryl, which rings are optionally substituted one or more R6, wherein R6 is lower alkyl, lower alkoxy, lower alkylsulfonyl, cyano, halogen, lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or is aryl, heterocyclyl or heteroaryl optionally substituted by lower alkyl or is cycloalkyl optionally substituted by lower alkyl; x is 0, 1, 2 or 3; or R1, R2 may form together with the N-atom heterocyclyl or heteroaryl, which rings are optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, lower alkylsulfonyl, halogen, cycloalkyl, benzyl or aryl; R3 is hydrogen or halogen; R4 is hydrogen or lower alkyl; R7 is hydrogen, halogen or lower alkyl; m is 1 or 2; when m is 2, R3 may be the same or not; n is 1 or 2; o is 1 or 2; when o is 2, R7 may be the same or not; or to a pharmaceutically suitable acid addition salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).